期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.767359
关键词
melioidosis; vaccine; Burkholderia pseudomallei; T-cell responses; IFN-gamma; type 2 diabetes
类别
资金
- Wellcome Trust Innovator Award [209274/Z/17/Z]
- Basque Government Postdoctoral Fellowship
- UCD2 Transatlantic One Health Alliance award
- Wellcome Trust Intermediate Clinical Fellowship [WT100174/Z/12/Z]
- NIHR Global Research Professorship [NIHR300791]
- Spanish Ministry of Science and Innovation [SEV-2016-0644]
- Welcome Trust Innovator Award [209274/Z/17/Z]
- National Institutes of Health-National Institute of Allergy and Infectious Diseases Large Scale T Cell Epitope Discovery Program [HHSN27220090046C]
- National Institutes of Health Research (NIHR) [NIHR300791] Funding Source: National Institutes of Health Research (NIHR)
Melioidosis, caused by Burkholderia pseudomallei, is potentially fatal and prevalent in Southeast Asia and Northern Australia. Immunization with BpOmpW antigen has shown promising results in enhancing immune responses, including antibody production and T-cell activation, suggesting its potential for clinical trials.
Melioidosis is a potentially fatal bacterial disease caused by Burkholderia pseudomallei and is estimated to cause 89,000 deaths per year in endemic areas of Southeast Asia and Northern Australia. People with diabetes mellitus are most at risk of melioidosis, with a 12-fold increased susceptibility for severe disease. Interferon gamma (IFN-gamma) responses from CD4 and CD8 T cells, but also from natural killer (NK) and natural killer T (NKT) cells, are necessary to eliminate the pathogen. We previously reported that immunization with B. pseudomallei OmpW (BpOmpW antigen) protected mice from lethal B. pseudomallei challenge for up to 81 days. Elucidating the immune correlates of protection of the protective BpOmpW vaccine is an essential step prior to clinical trials. Thus, we immunized either non-insulin-resistant C57BL/6J mice or an insulin-resistant C57BL/6J mouse model of type 2 diabetes (T2D) with a single dose of BpOmpW. BpOmpW induced strong antibody responses, stimulated effector CD4(+) and CD8(+) T cells and CD4(+) CD25(+) Foxp3(+) regulatory T cells, and produced higher IFN-gamma responses in CD4(+), CD8(+), NK, and NKT cells in non-insulin-resistant mice. The T-cell responses of insulin-resistant mice to BpOmpW were comparable to those of non-insulin-resistant mice. In addition, as a precursor to its evaluation in human studies, humanized HLA-DR and HLA-DQ (human leukocyte antigen DR and DQ isotypes, respectively) transgenic mice elicited IFN-gamma recall responses in an enzyme-linked immune absorbent spot (ELISpot)-based study. Moreover, human donor peripheral blood mononuclear cells (PBMCs) exposed to BpOmpW for 7 days showed T-cell proliferation. Finally, plasma from melioidosis survivors with diabetes recognized our BpOmpW vaccine antigen. Overall, the range of approaches used strongly indicated that BpOmpW elicits the necessary immune responses to combat melioidosis and bring this vaccine closer to clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据